Amar U. Kishan, M.D., presents data about stereotactic body radiation therapy at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018
ITN Contributing Editor Greg Freiherr interviews researchers about SBRT results.

With its shorter course of treatment, stereotactic body radiation therapy (SBRT) has long been preferred for patients with prostate cancer, particularly given that this form of cancer has appeared to be more sensitive to higher doses per treatments. Concern has lingered, however, about its safety. Those concerns have been put to rest for low and intermediate-risk prostate cancer, according to a researcher from the University of California, Los Angeles.

Whole-brain radiotherapy can be delivered more safely to patients with brain metastases by avoiding the hippocampus, according to a randomized phase III NRG Oncology trial. Trial results were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, Oct. 21-24 in San Antonio, Texas.

Artificial intelligence (AI) will not force specialists in radiation oncology from their jobs but rather make them better at the jobs only they can do, said speakers at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas.

Artificial intelligence (AI) will not force specialists in radiation oncology from their jobs but rather make them better at the jobs only they can do, said speakers at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas.

The first report of a large, international clinical trial shows that, for men who show signs of prostate cancer after surgical removal of their prostates, extending radiation therapy to the pelvic lymph nodes combined with adding short-term hormone therapy to standard treatment can extend the amount of time before their cancer spreads.

Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one kidney as it is for those who have two, according to an analysis of the largest-ever, international dataset of solitary kidney patients to receive this emerging treatment. The findings will be presented today at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

In a 10-year study of women who received radiation therapy to treat early-stage breast cancer, those receiving fewer, larger individual doses experienced similarly low rates of late-onset side effects as those undergoing conventional radiation therapy. Findings from the multi-institutional U.K. FAST clinical trial was at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Efficiency is the root of value-based medicine. Efficiency boosts productivity, as it lowers cost and increases patient comfort. It accomplishes this medical trifecta by helping to keep schedules on track and, thereby, satisfying patients. Effectiveness too is impacted, as it is intertwined with efficiency.

In radiology, where workflow and productivity go hand in hand, no single technology has greater potential to impact efficiency than picture archiving and communication systems (PACS).

Adding radiation therapy or surgery to systemic therapy for stage IV lung cancer patients whose cancer has spread to a limited number of sites can extend overall survival time significantly, according to new results from a multicenter, randomized, controlled phase II study. The findings will be presented today at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation surgery but can lower that risk even further with radiation therapy, finds a new long-term clinical trial report. These 12-year follow-up data from the only prospective, randomized trial to compare recurrence outcomes after treatment for low-risk ductal carcinoma in situ (DCIS) was presented on Oct. 21 at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

The Elekta Unity with 1.5T MRI embedded as a targeting system appeared at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas. The system is being sold in Europe and could soon enter the U.S. marketplace. (Photo courtesy of Elekta)

A linear accelerator combined with high-field MRI could soon be on the U.S. market. If U.S. regulators do as expected, it will be the second such system.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now